Humacyte (HUMA) Expected to Announce Earnings on Monday

Humacyte (NASDAQ:HUMA) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Humacyte to post earnings of ($0.15) per share and revenue of $0.94 million for the quarter.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million for the quarter, compared to analyst estimates of $0.46 million. On average, analysts expect Humacyte to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Humacyte Stock Performance

Shares of NASDAQ:HUMA opened at $2.48 on Friday. The company’s 50 day moving average price is $2.40 and its two-hundred day moving average price is $2.56. Humacyte has a 12-month low of $1.15 and a 12-month high of $8.24. The firm has a market cap of $384.70 million, a PE ratio of -3.59 and a beta of 1.90. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. D. Boral Capital restated a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Wednesday, July 23rd. Benchmark decreased their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. HC Wainwright began coverage on shares of Humacyte in a research report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Humacyte from a “sell” rating to a “hold” rating in a research report on Saturday. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Humacyte has an average rating of “Moderate Buy” and a consensus price target of $11.71.

Institutional Trading of Humacyte

A hedge fund recently raised its stake in Humacyte stock. Geode Capital Management LLC boosted its stake in Humacyte, Inc. (NASDAQ:HUMA) by 33.4% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,948,508 shares of the company’s stock after purchasing an additional 738,142 shares during the period. Geode Capital Management LLC owned about 1.90% of Humacyte worth $6,163,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.